Penetrium Bioscience Inc. (KOSDAQ:187660)
South Korea · Delayed Price · Currency is KRW 5,770.00
+140.00 (2.49%)
At close: Oct 23, 2026
Penetrium Bioscience Revenue
In the year 2024, Penetrium Bioscience had annual revenue of 9.74B KRW, down -29.33%. That makes Penetrium Bioscience the 38,584th largest company in the world by revenue and 2,438th in South Korea.
Revenue
9.74B
Revenue Growth
-29.33%
P/S Ratio
32.43
Revenue / Employee
60.91M
Employees
160
Market Cap
315.98B
Revenue by Segment
- Clinical Business Agency 9.29B 95.4%
- Rental Business 429.83M 4.4%
- Other Business 23.10M 0.2%
Fiscal year ended Dec 31, 2024 See the full Penetrium Bioscience breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.74B | -4.05B | -29.33% |
| Dec 31, 2023 | 13.79B | -1.09B | -7.34% |
| Dec 31, 2022 | 14.88B | 904.78M | 6.47% |
| Dec 31, 2021 | 13.98B | 857.61M | 6.54% |
| Dec 31, 2020 | 13.12B | 2.91B | 28.55% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| DreamCIS | 73.28B |
| HLB bioStep | 72.15B |
| C&R Research | 63.55B |
| DT&CRO CO. | 49.00B |
| Kolmar BioTech | 40.30B |
| BioInfra | 25.62B |
| P&K Skin Research Center | 23.67B |
| Ingenia Therapeutics | 7.42B |